Senior Trump administration officials are spending their last weeks in office throwing sand into the gears of government, gumming up the operation of public health agencies and dismantling protections against political interference in the actions...

Blueprint gains broader FDA label for Gavreto FDA approved Gavreto pralsetinib from Blueprint Medicines Corp. (NASDA:BLUE) to treat advanced or metastatic RET-mutant medullary thyroid cancer and RET fusion-positive, radioactive iodine-refractory thyroid cancer in patients at...

After its latest readout positioned the company to seek FDA authorization of its COVID-19 vaccine, Moderna has begun to look ahead to unblinding the Phase III trial of mRNA-1273 so participants who received a placebo can be...

AZ begins U.S. Phase III vaccine studyAstraZeneca plc (LSE:AZN; NYSE:AZN) announced Monday the beginning of the 30,000-volunteer U.S. Phase III D8110C00001 trial of AZD1222 to prevent COVID-19. The U.S. Biomedical Advanced Development Authority (BARDA) is...